Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial.

被引：10

作者：

Curigliano, Giuseppe

Gainor, Justin F.

Griesinger, Frank

Thomas, Michael

Subbiah, Vivek

Baik, Christina S.

Tan, Daniel Shao-Weng

Lee, Dae Ho

Misch, Daniel

Garralda, Elena

Kim, Dong-Wan

Paz-Ares, Luis G.

Mazieres, Julien

Liu, Stephen V.

Kalemkerian, Gregory Peter

Houvras, Yariv

Bowles, Daniel W.

Mansfield, Aaron Scott

Zalutskaya, Alena

van der Wekken, Anthonie J.

机构：

[1] IRCCS, European Inst Oncol, Milan, Italy

[2] Univ Milan, Milan, Italy

[3] Massachusetts Gen Hosp, Boston, MA 02114 USA

[4] Carl von Ossietzky Univ Oldenburg, Pius Hosp, Oldenburg, Germany

[5] Heidelberg Univ, Thoraxklin, Thorac Oncol, Heidelberg, Germany

[6] Translat Lung Res Ctr Heidelberg TLRC H, Heidelberg, Germany

[7] German Ctr Lung Res DZL, Heidelberg, Germany

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] Univ Washington, Sch Med, Seattle, WA 98195 USA

[10] Natl Canc Ctr Singapore, Singapore, Singapore

[11] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[12] Helios Clin Emil Behring, Berlin, Germany

[13] Vall Hebron Univ Hosp HUVH, Vall Hebron Inst Oncol VHIO, Med Oncol, Barcelona, Spain

[14] Seoul Natl Univ Hosp, Seoul, South Korea

[15] Hosp Univ 12 Octubre, Madrid, Spain

[16] Inst Univ Canc, Toulouse, France

[17] Georgetown Univ, Sch Med, Dept Hematol & Oncol, Washington, DC USA

[18] Univ Michigan, Ann Arbor, MI 48109 USA

[19] Weill Cornell Med Coll, New York, NY USA

[20] Univ Colorado, Sch Med, Aurora, CO USA

[21] Mayo Clin, Rochester, MN USA

[22] Blueprint Med Corp, Cambridge, MA USA

[23] Univ Groningen, Groningen, Netherlands

[24] Univ Med Ctr Groningen, Groningen, Netherlands

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.9089

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9089

引用

页数：3

共 50 条

[1] Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer
Zhou, Qing
Zhao, Jun
Chang, Jianhua
Wang, Huijie
Fan, Yun
Wang, Ke
Wu, Gang
Nian, Weiqi
Sun, Yuping
Sun, Meili
Wang, Xiangcai
Shi, Huaqiu
Zheng, Xiangqian
Yao, Sheng
Qin, Mengmeng
Shen, Zhenwei
Yang, Jason
Wu, Yi-Long
[J]. CANCER, 2023, 129 (20) : 3239 - 3251
[2] Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Griesinger, F.
Curigliano, G.
Thomas, M.
Subbiah, V.
Baik, C. S.
Tan, D. S. W.
Lee, D. H.
Misch, D.
Garralda, E.
Kim, D. -W.
van der Wekken, A. J.
Gainor, J. F.
Paz-Ares, L.
Liu, S., V
Kalemkerian, G. P.
Houvras, Y.
Bowles, D. W.
Mansfield, A. S.
Lin, J. J.
Smoljanovic, V.
Rahman, A.
Kong, S.
Zalutskaya, A.
Louie-Gao, M.
Boral, A. L.
Mazieres, J.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (11) : 1168 - 1178
[3] Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.
Subbiah, Vivek
Cassier, Philippe A.
Siena, Salvatore
Alonso, Guzman
Paz-Ares, Luis G.
Garrido, Pilar
Nadal, Ernest
Curigliano, Giuseppe
Vuky, Jacqueline
Lopes, Gilberto
Kalemkerian, Gregory Peter
Bowles, Daniel W.
Seetharam, Mahesh
Chang, Jianhua
Zhang, Hui
Ye, Chaoyang
Green, Jennifer
Zalutskaya, Alena
Schuler, Martin H.
Fan, Yun
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Pralsetinib in patients with RET fusion-positive non-small cell lung cancer: A plain language summary of the ARROW study
Griesinger, Frank
Curigliano, Giuseppe
Subbiah, Vivek
Baik, Christina S.
Tan, Daniel S. W.
Lee, Dae H.
Misch, Daniel
Garralda, Elena
Kim, Dong-Wan
van der Wekken, Anthonie J.
Gainor, Justin F.
Paz-Ares, Luis
Liu, Stephen, V
Kalemkerian, Gregory P.
Bowles, Daniel W.
Mansfield, Aaron S.
Lin, Jessica J.
Smoljanovic, Vlatka
Rahman, Ahmadur
Zalutskaya, Alena
Louie-Gao, Melinda
Boral, Andy L.
Mazieres, Julien
[J]. FUTURE ONCOLOGY, 2024, 20 (06) : 297 - 306
[5] Analysis of Resistance Mmechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study
Gainor, J.
Curigliano, G.
Doebele, R. C.
Lin, J. J.
Ou, S. -H.
Miller, S.
Turner, C. D.
Subbiah, V.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S5 - S5
[6] Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer
Nguyen, Ly
Monestime, Shanada
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (07) : 527 - 533
[7] Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion plus Non-Small Cell Lung Cancer
Zhou, Q.
Wu, Y.
Chang, J.
Wang, H.
Fan, Y.
Zhao, J.
Wu, G.
Sun, Y.
Sun, M.
Wang, X.
Shi, H.
Nian, W.
Wang, K.
Zheng, X.
Qu, L.
Yao, S.
Shen, Z.
Li, P.
Yang, J.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S889 - S890
[8] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
Gao, Ming
Zhang, Xia
Yan, Huan
Sun, Decong
Yang, Xuejiao
Yuan, Fang
Ju, Yanfang
Wang, Lijie
Wang, Jinliang
Zhao, Wei
Zhang, Dong
Li, Lin
Xu, Xiaoyun
Ma, Junxun
Hu, Yi
Zhang, Xiaotao
[J]. SUPPORTIVE CARE IN CANCER, 2023, 31 (12)
[9] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
Ming Gao
Xia Zhang
Huan Yan
Decong Sun
Xuejiao Yang
Fang Yuan
Yanfang Ju
Lijie Wang
Jinliang Wang
Wei Zhao
Dong Zhang
Lin Li
Xiaoyun Xu
Junxun Ma
Yi Hu
Xiaotao Zhang
[J]. Supportive Care in Cancer, 2023, 31
[10] Updated efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion plus non-small cell lung cancer
Zhou, Q.
Wu, Y-L.
Zhao, J.
Chang, J.
Wang, H.
Fan, Y.
Wang, K.
Wu, G.
Nian, W.
Gong, Y.
Sun, Y.
Sun, M.
Wang, X.
Shi, H.
Zheng, X.
Qin, M.
Duan, X.
Shen, Z.
Yao, S.
Yang, J.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1593 - S1593

← 1 2 3 4 5 →